Long-Term Benefits of Anti-CD20 Drugs in Relapsing MS

(MedPage Today) -- B-cell therapy for multiple sclerosis (MS) was first approved in 2017, after the anti-CD20 agent ocrelizumab (Ocrevus) demonstrated its ability to strongly suppress the acute inflammatory activity and MRI lesions associated with...